C
RVNC

Covestor’s Revance Therapeutics, Inc. RVNC Stock Holding History

Covestor’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-26
Closed – – 2857
2024
Q4 		$0 Buy
26
+2
+8% +$9 ﹤0.01% 2855
2024
Q3 		$0 Sell
24
-2
-8% -$10 ﹤0.01% 2880
2024
Q2 		$0 Buy
26
+16
+160% +$55 ﹤0.01% 2859
2024
Q1 		$0 Sell
10
-1
-9% -$6 ﹤0.01% 2850
2023
Q4 		$0 Buy
11
+5
+83% +$41 ﹤0.01% 2827
2023
Q3 		$0 Sell
6
-1
-14% -$19 ﹤0.01% 2824
2023
Q2 		$0 Sell
7
-1
-13% -$31 ﹤0.01% 2767
2023
Q1 		$0 Hold
8
– – ﹤0.01% 2697
2022
Q4 		$0 Sell
8
-3
-27% -$69 ﹤0.01% 2719
2022
Q3 		$0 Sell
11
-2
-15% -$41 ﹤0.01% 2733
2022
Q2 		$0 Sell
13
-12
-48% -$185 ﹤0.01% 2453
2022
Q1 		$0 Sell
25
-6
-19% -$91 ﹤0.01% 2495
2021
Q4 		$1K Buy
+31
New +$517 ﹤0.01% 2022

Other funds holding RVNC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Covestor's RVNC Position: Q1 2025 in Review

Covestor sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 26 shares.

Covestor first reported a position in RVNC in Q4 2021 and held it in 13 quarters. The position peaked at $1K in Q4 2021. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.

  • Covestor reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
  • Covestor sold 26 Revance Therapeutics, Inc. shares in Q1 2025.
  • Covestor first reported a position in Revance Therapeutics, Inc. in Q4 2021 and held it in 13 quarters.
  • Covestor's Revance Therapeutics, Inc. position peaked at $1K in Q4 2021.
  • 1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.

Based on Covestor's 13F filing for Q1 2025, filed 12 May 2025.